Mammary Cell News 10.42 October 25, 2018 | |
| |
TOP STORYRNA Thought to Spread Cancer Shows Ability to Suppress Breast Cancer Metastasis Researchers discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, suggesting a potential new area of therapeutic investigation. [Press release from the University of Texas MD Anderson Cancer Center discussing online prepublication in Nature Genetics] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators developed an anti-HER2/CD3 T cell-dependent bispecific antibody that selectively targeted HER2-overexpressing tumor cells with high potency, while sparing cells that expressed low amounts of HER2 found in normal human tissues. [Sci Transl Med] Abstract Researchers revealed that a physiological concentration of estrogens efficiently induced TOP2β-dependent DSBs in the absence of BRCA1 in breast cancer cells arrested in G1 phase. [Proc Natl Acad Sci USA] Abstract Scientists reported that gene copy numbers and expression levels of Nuclear Factor IB (NFIB), a recently identified oncogene in small cell lung cancer, were preferentially increased in triple-negative breast cancer compared to other breast cancer subtypes. [J Pathol] Abstract Researchers identified that miR-3178 was significantly reduced in triple-negative breast cancer (TNBC), and the low miR-3178 expression correlated with poor overall survival in TNBC but not in non-TNBC. [Cell Death Dis] Full Article miR4673 Improves Fitness Profile of Neoplastic Cells by Induction of Autophagy Scientists demonstrated a microRNA-mediated mechanism that effectively improved fitness of SKBR3 mammary carcinoma cells by cytoplasmic reprogramming. [Cell Death Dis] Full Article Investigators showed that (-)-oleocanthal, a phenolic compound isolated from olive oil, selectively impaired MDA-MB-231 cell proliferation and viability without affecting the ability of non-tumoral MCF10A cells to proliferate or their viability. [Biochim Biophys Acta] Abstract In vitro, antiproliferative efficacy was dependent upon cell type, size of the spheroids, and treatment scheduling, resulting in subsequent changes between tested conditions and in vivo results. [Int J Nanomedicine] Full Article GCSH Antisense Regulation Determines Breast Cancer Cells’ Viability The initial analysis revealed glycine cleavage system protein H (GCSH)-overexpression of the protein-coding transcript variant 1 in breast cancer cells and tissue. [Sci Rep] Full Article LncRNA BLAT1 Is Upregulated in Basal-Like Breast Cancer through Epigenetic Modifications Investigators performed a comparative analysis of basal-like breast cancer (BLBC) versus non-BLBC using microarray profiling and RNA sequencing of primary breast cancer. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSmiRNA and Long Non-Coding RNA: Molecular Function and Clinical Value in Breast and Ovarian Cancers The authors discuss the existing knowledge regarding the involvement of miRNAs and long non-coding RNAs in the molecular background of breast and ovarian malignancies, to highlight their clinical utility in improving disease management. [Expert Rev Mol Diagn] Abstract The authors describe the current status of immunological and targeted treatments from a hypothesis driven perspective. [Expert Rev Anticancer Ther] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSTHERACLION Announces Presentation of Results in Benign and Malignant Breast Tumors Theraclion announced today the presentation of results of two clinical studies as well as the results published on in the International Journal of Hyperthermia on the treatment by Echopulse® of benign and malignant breast tumors. [Press release from Theraclion discussing research presented at Focused Ultrasound Foundation Symposium, Reston] Press Release First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented Celgene Corporation announced the first results from the IMpassion130 study evaluating paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with atezolizumab in patients with first-line locally advanced triple negative breast cancer. [Press release from Celgene Corporation discussing research presented at European Society for Medical Oncology Congress, Munich] Press Release | |
| |
INDUSTRY NEWSVoluntis Announces End of Multi-Cancer Extension for Solution Developed with Roche Pharma France Voluntis announces Roche Pharma France’s decision to end the agreement to extend the ZEMY solution, initially developed in breast cancer, to all solid tumors. In breast cancer, Roche Pharma France will continue to sponsor the ongoing clinical study. [Voluntis] Press Release Case Comprehensive Cancer Center Receives $3M NIH Grant for Health Disparities Research The Case Comprehensive Cancer Center has received a three-year, $3,194,947 grant from the National Cancer Institute to investigate colorectal and breast cancer health disparities. [Case Western Reserve University] Press Release | |
| |
POLICY NEWSLeading Cancer-Research Charity Takes Tough Stance on Bullying One of the world’s biggest funders of cancer research has launched an anti-bullying policy that could lead to the withdrawal of funding from scientists whose institutions uphold allegations made against them. The policy, announced by Cancer Research UK, makes the charity the second major UK research funder to introduce anti-bullying and anti-harassment rules. [Nature News] Editorial China Hides Identities of Top Scientific Recruits amidst Growing US Scrutiny China’s flagship science talent recruitment program, the Thousand Talents Plan, has gone underground amidst intensifying scrutiny by United States government agencies for China’s suspected role in the theft of US technologies and intellectual property. [Nature News] Editorial First Analysis of ‘Pre-Registered’ Studies Shows Sharp Rise in Null Findings Studies that fail to find a positive result are often filed away, never to see the light of day, which leads to a publication bias that compromises the credibility of scientific literature. An analysis now suggests that registering and peer-reviewing study protocols before research is conducted could improve this ‘file-drawer problem’, and help to correct the existing publication bias towards positive findings. [Nature News] Editorial
| |
EVENTSNEW Gordon Research Conference: Mammary Gland Biology Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Researcher Positions – Cancer (University of Bergen) NEW Research Fellow – Immunology (King’s College London) Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame) Research Associate – Immunology (King’s College London) Research Associate – CAR T-Cell Immunotherapy (King’s College London) Postdoctoral Fellowship – Epigenetics and RNA Biology (UmeÃ¥ University) Postdoctoral Research Fellow – Mammary Stem Cell Biology (University of Southampton) Team Leader – ER Positive Breast Cancer (Institute of Cancer Research) Assistant/Associate/Professor – Department of Cancer Biology (University of Cincinnati) Postdoctoral Fellow – Immunotherapy of Breast Cancer (Boston University School of Medicine) Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine) Postdoctoral Position – Cancer Biology (GIGA – Universite de Liege) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|